{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-073046","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.115060+00:00","generated_at":"2026-06-01T04:39:23.890097+00:00","sec_items":["3.03","5.03","5.07","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nkarta shareholders approve doubling authorized shares; elects Dr. Vratsanos to board","bullets":["Shareholders approved increasing authorized common shares from 100M to 200M.","Elected three Class I directors: Paul Hastings, Angela Thedinga, and new member George Vratsanos.","Ratified Ernst & Young as independent auditor for fiscal 2024.","Press release highlights Dr. Vratsanos' R&D leadership at Jnana, Janssen, Novartis, Roche, BMS.","Nkarta focuses on NK cell therapy for lupus nephritis with NKX019 program."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-073046","json":"https://secwatch.observer/filing/0000950170-24-073046.json","markdown":"https://secwatch.observer/filing/0000950170-24-073046.md","text":"https://secwatch.observer/filing/0000950170-24-073046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024073046/0000950170-24-073046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024073046/nktx-20240613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:39:23.890097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}